Detection of hepatic metastases from colorectal carcinoma using indium-111 (111In) labeled monoclonal antibody (mAB): MSKCC experience with mAb 111In-C110

Divgi, Chaitanya; McDermott, Kathleen; Johnson, David K.; Schnobrich, Karen E.; Finn, Ronald D.; Cohen, Alfred M.; Larson, Steven M.

doi:10.1016/0883-2897(91)90008-9

Cited by 12 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the EOTUBE-bsMAb complexes were held together monovalently, they would readily dissociate, providing a “slow-release” of EOTUBE, which would then be removed rapidly. While the pretargeting procedure was more complex than injecting a directly radiolabeled antibody, this method showed metastatic lesions in the liver with good contrast from surrounding normal liver, while 111 In-labeled anti-CEA IgG being used at the time often showed tumors as “cold” lesions due to higher uptake in normal liver 57,58…”

Section: Why Pretargeting?mentioning

confidence: 99%

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy

Sharkey

Rossi

McBride

et al. 2010

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

The selective delivery of therapeutic radionuclides is a promising approach for treating cancer. Antibody-targeted radionuclides are of particular interest, with two products approved for the treatment of certain forms of non-Hodgkin lymphoma. However, for many other cancers, radioimmunotherapy (RAIT) has been ineffective, being limited by prolonged exposure to the highly radiosensitive bone marrow. An alternative approach, known as pretargeting, separates radionuclide from the antibody, allowing the radiation to be delivered on a small molecule that can quickly and efficiently migrate into the tumor, and then rapidly clear from the body with minimal retention in tissues. Several pretargeting methods have been developed that differ in the way they selectively capture the radionuclide. This review focuses on the development of a novel form of bispecific monoclonal antibody (bsMAb) pretargeting that uses a unique radiolabeled haptenpeptide system that can be modified to bind a number of therapeutic and imaging radionuclides. Together with a specialized recombinant humanized bsMAb prepared with by a technique known as the Dock-and-Lock (DNL) method, this pretargeting procedure has been examined in a number of different animal models, showing a high level of sensitivity and specificity for localizing tumors, and improved efficacy with less hematologic toxicity associated with directly radiolabeled IgG. The bsMAb is a tri-Fab structure, having 2 binding arms for the tumor antigen and one capable of binding a hapten-peptide. Preclinical studies were preformed to support the clinical use of a bsMAb (TF2) and a hapten-peptide bearing a single DOTA moiety . A Phase 0 trial found an 131 I-TF2 that targets carcinoembryonic antigen (CEA) was stable in vivo, quickly clears from the blood, and localizes known tumors. The first-in-patient pretargeting experience with the 111 In-IMP-288 also observed rapid clearance and low tissue (kidney) retention, as well as localization of tumors, providing initial promising evidence for developing these materials for radioimmunotherapy. Corresponding author: RM Sharkey, Ph.D., Center for Molecular Medicine and Immunology, 520 Belleville Ave, Belleville, NJ 07109; Telephone: 973-844-7121; rmsharkey@gscancer.org. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. It is not surprising that RAIT's first clinical success occurred in lymphoma, given the radiation sensitivity of hematologic malignancies that could achieve complete responses with ~700 cGy, but responses have even been observed even when tumor uptake is not visualized. [20][21][22] Inde...

show abstract

Section: Why Pretargeting?mentioning

confidence: 99%

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy

Sharkey

Rossi

McBride

et al. 2010

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, we prefer to use anti‐CEA mAbs whenever possible to evaluate patients with liver metastases. This is supported by two recent articles, by Haseman et al42 and Divgi et al,43 whereby In‐111 anti‐CEA mAbs (ZCE 025 or C110) correctly identified hepatic metastasis as “hot” spots in 44% and 81% of patients, respectively. In 173 patients with occult CEA‐producing cancer, mAb imaging accurately predicted the presence of disease in 91% of patients, and its absence in 84% of patients compared to CT scanning, and thus appears to be the best diagnostic imaging procedure currently available in this clinical setting 44…”

Section: Radiolabeled Monoclonal Antibodiesmentioning

confidence: 57%

Imaging strategies in hepatic metastases from colorectal carcinoma

Doerr

Kulaylat

Abdel-Nabi

1995

J Hep Bil Pancr Surg

View full text Add to dashboard Cite

Abstract:Approximately two-thirds of metastatic lesions that develop following curative resection of colorectal cancer occur in the liver and lung. In select groups of patients, resection of these lesions is associated with increased 5-year survival. In the liver, precise preoperative documentation of the presence, location, number, and relationship of these lesions to vascular structure is crucial in the selection of candidates for curative resection. Computed tomography with arterial portography (CTAP), intraoperative ultrasonography (IOUS), positron emission tomographic (PET) scan, and radionuclide scanning, including radiolabeled monoclonal antibody imaging, are emerging as the procedures of choice in the preoperative and intraoperative evaluation of metastatic c01orectal cancer to the liver.

show abstract

“…Four days later, the patient received 111 In-EOTUBE. This clinical investigation reported a detection sensitivity of 95% for known tumor lesions, some detected within 4 h of the 111 In-EOTUBE injection, including hepatic metastases, a site where other clinical studies using an intact 111 In-anti-CEA IgG frequently had difficulty because of the high background activity in the liver 36, 37.…”

Section: The Pretargeting Alternativementioning

confidence: 84%

Pretargeted Molecular Imaging and Radioimmunotherapy

et al. 2012

View full text Add to dashboard Cite

Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb) localize within a tumor by virtue of its anti-tumor binding site(s) before administering a small, fast-clearing radiolabeled compound that then attaches to the other portion of the bsMAb. The compound's rapid clearance significantly reduces radiation exposure outside of the tumor and its small size permits speedy delivery to the tumor, creating excellent tumor/nontumor ratios in less than 1 hour. Haptens that bind to an anti-hapten antibody, biotin that binds to streptavidin, or an oligonucleotide binding to a complementary oligonucleotide sequence have all been radiolabeled for use by pretargeting. This review will focus on a highly flexible anti-hapten bsMAb platform that has been used to target a variety of radionuclides to image (SPECT and PET) as well as treat tumors.

show abstract

Detection of hepatic metastases from colorectal carcinoma using indium-111 (111In) labeled monoclonal antibody (mAB): MSKCC experience with mAb 111In-C110

Cited by 12 publications

References 13 publications

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy

Imaging strategies in hepatic metastases from colorectal carcinoma

Pretargeted Molecular Imaging and Radioimmunotherapy

Contact Info

Product

Resources

About